Kalbe Farma Tbk PT : Dividend for Year 2010 Will Increase Significantly

Jakarta, April 18, 2011 - PT Kalbe Farma Tbk. and Subsidiaries ('Kalbe') today announced its plans to distribute dividend of approximately 50% of its 2010 net profit, or equivalent to approximately Rp 643 billion, a sharp increase of over 2.5 times compared to dividend distributed on 2009 net profit of Rp 254 billion. The proposed dividend payment for year 2010 will be brought up for shareholders' approval in the Annual General Meeting of Shareholders to be convened in May 2011.

'We are delighted to announce to our shareholders that Kalbe will increase dividend payout ratio of 50% of our 2010 net profit,' remarked Kalbe's Finance Director, Vidjongtius. 'Our decision to increase dividend payment is based on our strong growth in profitability and Kalbe's solid cash flow generation. We are also confident that with our current financial position, Kalbe will be able to finance all capital expenditure and working capital requirements to continuously improve our outstanding performance. In addition to the development of its existing 4 business portfolios, Kalbe will also push forward its business development strategy through acquisitions. We have formed a Strategic Investments unit, tasked with identifying and executing suitable acquisition opportunities for Kalbe. We expect that this Strategic Investments unit will support Kalbe in realizing its business development strategy in the future'.

Kalbe recorded net sales of Rp 10.23 trillion in year 2010, up by 12.5% from that in year 2009. Sales growth is accompanied by solid expansion in net profit by 38.5%, to Rp 1.29 trillion in 2010. Meanwhile, earnings per share rose by 41.5% to Rp 137 per share. As of December 31, 2010, Kalbe has a solid cash position of Rp 1.90 trillion. From the share repurchase program conducted since 2007, the Company has bought back 780,990,000 treasury stocks, or equivalent to 7.7% of total paid-up capital. At current market price, the treasury stocks are worth approximately Rp 2.8 trillion.The ongoing appreciation of the Rupiah against foreign currencies also positively impacts the Company's financial performance.

'This significant increase in dividend, demonstrates the Management's ongoing commitment to deliver increasing yield and value to the shareholders, now and in the future, commented Kalbe's President Director, Irawati Setiady. 'The increase in dividend payout ratio is part of the series of policy to continuously enhance superior yield to the shareholders, which has been implemented in the past few years, such as the share repurchase program and the repayment of the Kalbe's debts. Further, we also believe that Kalbe's healthy financial condition has well positioned Kalbe to continuously grow and develop, both organically and inorganically'.

Kalbe at a Glance
PT Kalbe Farma Tbk. ('Kalbe') is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has a broad and strong portfolio of brands in prescription pharmaceuticals (Cefspan, Brainact, Broadced, etc), OTC pharmaceuticals (Woods, Promag, Mixagrip, Komix, etc), energy drinks (Extra Joss, E-Juss)
and nutritional products (Milna, Prenagen, Diabetasol, etc), complemented with a robust distribution arm covering much of the
Indonesian archipelago. Since 1991, Kalbe's shares have been listed on the Indonesia
Stock Exchange (IDX: KLBF).